Nicole Lamanna, MD

Articles

Future of Treatment of B-Cell Malignancies

January 10th 2024

Nicole Lamanna, MD, looks ahead at the future of treatment of B-cell malignancies, highlighting exciting therapeutic developments.

Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL

January 3rd 2024

A hematologist/oncologist discusses ongoing research on targeted therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Treatment Sequencing for Patients With B-Cell Malignancies

January 3rd 2024

Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.

Adverse Events for BTK Inhibitors and BCL2 Inhibitors in CLL

December 27th 2023

Expert perspectives on the toxicities seen with targeted therapies in chronic lymphocytic leukemia and how they’re mitigated and managed.

Recent Data in Relapsed/Refractory CLL/SLL

December 27th 2023

An expert on hematologic malignancies discusses recent data from ASH 2023 in relapsed/refractory CLL/SLL, highlighting the ALPINE study investigating zanubrutinib versus ibrutinib.

Zanubrutinib Plus Sonrotoclax in Patients With Treatment-Naïve CLL/SLL

December 21st 2023

Nicole Lamanna, MD, discusses the results from the ongoing BGB-11417-101 study investigating combination zanubrutinib plus sonrotoclax in patients with treatment-naïve CLL/SLL.

CLL: Updated Data in the Frontline Setting Presented at ASH 2023

December 21st 2023

A hematologist/oncologist previews updated data presented at ASH 2023 for patients with B-cell malignancies.

Targeted Therapy and Role of Biomarkers in B-Cell Malignancies

December 21st 2023

Nicole Lamanna, MD, gives an overview of targeted therapies and the role of prognostic markers in the treatment of B-cell malignancies.

Looking Ahead to Upcoming Presentations at ASH 2023

December 5th 2023

Expert insights into the evolving treatment landscape for chronic lymphocytic leukemia (CLL), emphasizing upcoming clinical data to be presented at ASH 2023.

Dr Lamanna on the Use of Novel Agents Following Progression in CLL

December 1st 2023

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Unmet Needs and Future Directions in Care in CLL

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.